The prognostic value of nuclear roundness and neopterin in ovarian cancer.
作者： C. Marth , A. Weger , E. Müller-Holzner , A.G. Zeimet , H. Moncayo-Naveda
DOI: 10.1016/0959-8049(93)90539-R
关键词:
摘要: Abstract The prognostic value of clinical factors, morphometric features and neopterin, a marker for macrophage activation, was investigated retrospectively in 68 ovarian carcinoma patients. Nuclear roundness good predictor patient survival. About 50% our patients showed neopterin concentrations above the cut-off level 275 μmol/mol creatinine. Interestingly, those with elevated urinary concentration, thus displaying sign activation cell-mediated immunity, had shorter survival than normal concentration. Applying multivariate Cox regression analysis, only independent parameters predicting were FIGO stage, residual disease, nuclear neopterin.
sci-hub.se 参考文章(26)
M Davy, R S Bush, E J Berle, A J Dembo, K Kjorstad, A E Stenwig, Prognostic factors in patients with stage I epithelial ovarian cancer. Obstetrics & Gynecology. ,vol. 75, pp. 263- 273 ,(1990)
S Marsoni, , V Torri, MG Valsecchi, C Belloni, U Bianchi, G Bolis, C Bonazzi, N Colombo, A Epis, G Favalli, A Gambino, F Landoni, R Maggi, S Pecorelli, S Presti, L Vassena, F Zanaboni, C Mangioni, Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)). British Journal of Cancer. ,vol. 62, pp. 444- 450 ,(1990) , 10.1038/BJC.1990.315
Helmut Wachter, Neopterin: Biochemistry-Methods-Clinical Application ,(1991)
Isaiah J. Fidler, Macrophages and Metastasis—A Biological Approach to Cancer Therapy: Presidential Address Cancer Research. ,vol. 45, pp. 4714- 4726 ,(1985)
Otto Dapunt, Gilbert J. Reibnegger, Alfred H. Bichler, Heinz M. Hetzel, Ernst R. Werner, Dietmar N. Fuchs, Helmut Wachter, Hermann Lutz, Lothar C. Fuith, Arno Hausen, Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Research. ,vol. 46, pp. 950- 955 ,(1986)
J. Schneider, L. Edler, W. Kleine, M. Volm, DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma. Archives of Gynecology and Obstetrics. ,vol. 248, pp. 45- 52 ,(1990) , 10.1007/BF02389589
E.E. Voest, J.C. van Houwelingen, J.P. Neijt, A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives European Journal of Cancer and Clinical Oncology. ,vol. 25, pp. 711- 720 ,(1989) , 10.1016/0277-5379(89)90208-3
C. Marth, R. Mull, G. Gastl, M. Herold, E. Steiner, G. Daxenbichler, H. Hetzel, Roswitha Flener, C. Huber, O. Dapunt, The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma Geburtshilfe Und Frauenheilkunde. ,vol. 49, pp. 987- 991 ,(1989) , 10.1055/S-2008-1036852
A.R. Weger, J.L. Lindholm, Discrimination of pancreatic adenocarcinomas from chronic pancreatitis by morphometric analysis. Pathology Research and Practice. ,vol. 188, pp. 44- 48 ,(1992) , 10.1016/S0344-0338(11)81154-4
W. Kühn, G. Feichter, J. Hanke, H. Rummel, M. Kaufmann, H. Schmid, Clinical course of ovarian cancer in relation to morphologic prognostic factors and cell kinetic parameters Geburtshilfe Und Frauenheilkunde. ,vol. 47, pp. 446- 451 ,(1987) , 10.1055/S-2008-1035849